Scilex Holding Company Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months
Scilex Holding Company (SCLX) had Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months of $4.11 million as of 2022-12-31, per its 10-K filed 2023-03-07.
Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Rolling Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths · last filed 2023-03-07
- 2022-12-31: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $4.11M.
| Period end | Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months |
|---|---|
| 2022-12-31 | $4.11M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |